Varughese, P. Incidence of pertussis in Canada. Canadian Medical Association Journal
1985; 132: 1041–1042.
Cherry, JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clinical Infectious Diseases
1999; 28 (Suppl. 2): S107–111.
Mattoo, S, Cherry, JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clinical Microbiology Reviews
2005; 18: 326–382.
Crowcroft, NS, et al.
How best to estimate the global burden of pertussis?
Lancet Infectious Diseases
2003; 3: 413–418.
Rohani, P, Drake, JM. The decline and resurgence of pertussis in the US. Epidemics
2011; 3: 183–188.
Moerman, L, et al.
The re-emergence of pertussis in Israel. Israel Medical Association Journal
2006; 8: 308–311.
Scheil, W, et al.
Pertussis in South Australia 1893 to 1996. Communicable Diseases Intelligence
1998; 22: 76–80.
Quinn, H, McIntyre, P. The impact of adolescent pertussis immunization, 2004–2009: lessons from Australia. Bulletin of the World Health Organization
2011; 89: 666–674.
Gzyl, A, et al.
Pertussis in Poland. International Journal of Epidemiology
2004; 33: 358–365.
Bamberger, ES, Srugo, I. What is new in pertussis?
European Journal of Pediatrics
2008; 167: 133–139.
Gangarosa, EJ, et al.
Impact of anti-vaccine movements on pertussis control: the untold story. Lancet
1998; 351: 356–361.
Wood, N, McIntyre, P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatric Respiratory Reviews
2008; 9: 201–211.
Rohani, P, Earn, DJD, Grenfell, BT. Opposite patterns of synchrony in sympatric disease metapopulations. Science
1999; 286: 968–971.
Broutin, H, et al.
Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proceedings of the Royal Society of London, Series B: Biological Sciences
2010; 277: 3239–3245.
Wearing, HJ, Rohani, P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathogens
2009; 5: e1000647.
Ntezayabo, B, De Serres, G, Duval, B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatric Infectious Disease Journal
2003; 22: 22–27.
Clarkson, JA, Fine, PE. The efficiency of measles and pertussis notification in England and Wales. International Journal of Epidemiology
1985; 14: 153–168.
Doyle, TJ, Glynn, MK, Groseclose, SL. Completeness of notifiable infectious disease reporting in the United States: an analytical literature review. American Journal of Epidemiology
2002; 155: 866–874.
Spokes, PJ, Quinn, HE, McAnulty, JM. Review of the 2008–2009 pertussis epidemic in NSW: notifications and hospitalisations. New South Wales Public Health Bulletin
2010; 21: 167–173.
Crowcroft, NS. Whooping cough – a continuing problem. British Medical Journal
2002; 324: 1537–1538.
He, Q, Mertsola, J. Factors contributing to pertussis resurgence. Future Microbiology
2008; 3: 329–339.
Fine, PE, Clarkson, JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet
1982; 1: 666–669.
Gay, NJ, Miller, E. Pertussis transmission in England and Wales. Lancet
2000; 355: 1553–1554.
Tanaka, M, et al.
Trends in pertussis among infants in the United States, 1980–1999. Journal of the American Medical Association
2003; 290: 2968–2975.
Campbell, H, et al.
Accelerating control of pertussis in England and Wales. Emerging Infectious Diseases
2012; 18: 38–47.
Cherry, JD. Pertussis in adults. Annals of Internal Medicine
1998; 128: 64–66.
Rohani, P, Earn, DJD, Grenfell, BT. Pertussis transmission in England and Wales – reply. Lancet
2000; 355: 1553–1554.
Nguyen, HTH, Rohani, P. Noise, nonlinearity and seasonality: the epidemics of whooping cough revisited. Journal of the Royal Society Interface
2008; 5: 403–413.
Keeling, MJ, Rohani, P. Modeling Infectious Diseases in Humans and Animals. Princeton, New Jersey: Princeton University Press, 2008.
Edwards, KM, et al.
Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics
1995; 96: 548–557.
Crowcroft, NS, Pebody, RG. Recent developments in pertussis. Lancet
2006; 367: 1926–1936.
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerging Infectious Diseases
2009; 15: 1206–1213.
Clark, TA, Messonnier, NE, Hadler, SC. Pertussis control: time for something new?
Trends in Microbiology
2012; 20: 211–213.
Cherry, JD. The present and future control of pertussis. Clinical Infectious Diseases
2010; 51: 663–667.
Sheridan, SL, et al.
Number and order of whole cell pertussis vaccines in infancy and disease protection. Journal of the American Medical Association
2012; 308: 454–456.
Versteegh, FGA, Edwards, KM. How to fight whooping cough?
Archives of Pediatrics and Adolescent Medicine
2012; 166: 389–391.
Tan, T, Trindade, E, Skowronski, D. Epidemiology of pertussis. Pediatric Infectious Disease Journal
2005; 24: S10–S18.
Shinall, MC, et al.
Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics
2008; 122: 1021–1026.
Fecsik, AI. Studies on antibody production: XI. Variation in the secondary response as a function of the interval between two antigenic stimuli. Journal of Experimental Medicine
1964; 120: 1041–1049.
Blennow, M, et al.
Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics
1988; 82: 293–299.
Taranger, J, et al.
Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine
1999; 18: 884–891.
Booy, R, et al.
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet
1992; 339: 507–510.
White, JM, et al.
The effect of an accelerated immunisation schedule on pertussis in England and Wales. Communicable Disease Report (CDR Review)
1996; 6: R86–91.
Jefferson, T, Rudin, M, DiPietrantonj, C. Systematic review of the effects of pertussis vaccines in children. Vaccine
2003; 21: 2003–2014.
Omer, SB, et al.
Nonmedical exemptions to school immunization requirements: Secular trends and association of state policies with pertussis incidence. Journal of the American Medical Association
2006; 296: 1757–1763.
Omer, SB, et al.
Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. American Journal of Epidemiology
2008; 168: 1389–1396.
Anderson, RM, May, RM, McLean, A. Possible demographic consequences of AIDS in developing countries. Nature
1988; 332: 228–234.
Anderson, RM, May, RM. Infectious Diseases of Humans: Dynamics and Control. Oxford, New York: Oxford University Press, 1991.
Wendelboe, AM, et al.
Duration of immunity against pertussis after natural infection or vaccination. Pediatric Infectious Disease Journal
2005; 24: S58.
Lavine, JS, Rohani, P. Resolving pertussis immunity and vaccine efficiency using incidence time series. Expert Review of Vaccines (in press).
Rohani, P, Zhong, X, King, AA. Contact network structure explains the changing epidemiology of pertussis. Science
2010; 330: 982–985.
Cherry, JD, Baraff, LJ, Hewlett, E. The past, present, and future of pertussis. The role of adults in epidemiology and future control. Western Journal of Medicine
1989; 150: 319–328.
Cherry, JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clinical Infectious Diseases
1999; 28 (Suppl 2): S112–117.
Skoff, TH, et al.
Early impact of the US Tdap vaccination program on pertussis trends. Archives of Pediatrics and Adolescent Medicine
2012; 166: 344–349.
van Boven, M, et al.
Pathogen adaptation under imperfect vaccination: implications for pertussis. Proceedings of the Royal Society of London, Series B: Biological Sciences
2005; 272: 1617–1624.
Schellekens, J, von Konig, C-HW, Gardner, P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatric Infectious Disease Journal
2005; 24: S19–S24.
Lavine, JS, King, AA, Bjørnstad, ON. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proceedings of the National Academy of Sciences USA
2011; 108: 7259–7264.
Aguas, R, Gonçalves, G, Gomes, MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infectious Diseases
2006; 6: 112–117.
Cattaneo, LA, et al.
The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. Journal of Infectious Diseases
1996; 173: 1256–1259.
Mooi, FR, van Loo, IHM, King, AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?
Emerging Infectious Diseases
2001; 7: 526–528.
Fry, NK, et al.
Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infection and Immunity
2001; 69: 5520–5528.
Mooi, FR, et al.
Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infection and Immunity
1998; 66: 670–675.
Borisova, O, et al.
Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clinical and Vaccine Immunology
2007; 14: 234–238.
Advani, A, et al.
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine
2011; 29: 3438–3442.
Kodama, A, et al.
Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. Journal of Clinical Microbiology
2004; 42: 5453–5457.
Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infection, Genetics and Evolution
2010; 10: 36–49.
Elomaa, A, et al.
Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine
2007; 25: 918–926.
Octavia, S, et al.
Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008–2010. Journal of Infectious Diseases
2012; 205: 1220–1224.
van Gent, M, et al.
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS ONE
2012; 7: e46407.
Schmidtke, AJ, et al.
Population diversity among Bordetella pertussis isolates, United States, 1935–2009. Emerging Infectious Diseases
2012; 18: 1248–1255.
Bajardi, P, et al.
Human mobility networks, travel restrictions, and the global spread of 2009 H1N1 pandemic. PLoS ONE
2011; 6: e16591.
Russell, CA, et al.
The global circulation of seasonal influenza A (H3N2) viruses. Science
2008; 320: 340–346.
Shin, SY, et al.
Drug-resistant pandemic (H1N1) 2009, South Korea. Emerging Infectious Diseases
2011; 17: 702–704.
Wensing, AM, et al.
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. Journal of Infectious Diseases
2005; 192: 958–966.
Wongsrichanalai, C, Pickard, AL. Epidemiology of drug-resistant malaria. Lancet Infectious Diseases
2002; 2: 209–218.
Preston, NW. Pertussis today. In: Wardlow, AC, Parton, R, eds. Pathogenesis and Immunity in Pertussis. Chichester, UK: John Wiley & Sons Ltd, 1988, pp. 1–19.
Blumenthal, D, et al.
Data withholding in genetics and the other life sciences: prevalences and predictors. Academic Medicine
2006; 81: 137–145.
Pisani, E, et al.
Time for fair trade in research data. Lancet
2010; 375: 703–705.